Categories: News

Champions Oncology to Announce Third Quarter Financial Results on Monday, March 18, 2019

HACKENSACK, NJ / ACCESSWIRE / March 6, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2019, on Monday, March 18, 2019, after market close.

The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PDT). To participate in the call, please call 877-407-8035 (domestic) or 201-689-8035 (international) ten minutes ahead of the call and give the verbal reference “Champions Oncology.”

A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 45132, or by accessing the Investor tab of the company’s website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs. The Company’s TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions primarily in Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

Investor Contacts:

David Miller
CFO
Champions Oncology, Inc
(551) 206-8104
dmiller@championsoncology.com

Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Champions Oncology, Inc.

View source version on accesswire.com:
https://www.accesswire.com/538125/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Monday-March-18-2019

user

Recent Posts

Arlington Medical Waste Disposal Company Addresses Rising Needlestick Injuries With Handy Guide

The CDC Reports Approximately 385,000 Needlestick and Sharps-Related Injuries Among U.S. Healthcare Workers AnnuallyARLINGTON, TX…

56 minutes ago

poLight ASA receives purchase order for TWedge® wobulator technical samples from a top tier consumer OEM customer

TØNSBERG, Norway, Nov. 21, 2024 /PRNewswire/ -- poLight ASA (OSE: PLT) today announced that the…

4 hours ago

Waud Capital Partners Releases First Annual Responsible Investing Report

CHICAGO, Nov. 21, 2024 /PRNewswire/ -- Waud Capital Partners ("Waud Capital"), a growth-oriented middle-market private equity…

4 hours ago

Rightway Partners with Curai Health to Expand Access to High-Quality, Affordable Virtual Care

NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Today, Rightway, a company transforming care navigation and pharmacy…

4 hours ago

Aires Tech Showcases Advanced Technology at UFC Performance Institute with “Next Frontier of UFC Training and Performance” Symposium

Symposium gathered top fighters, neuroscientists, and media together in New York City on eve of UFC…

4 hours ago

Space-Grown Brain Organoids Help Advance New Neurological Treatment

Startup Leverages ISS National Lab to Test Viral Vector That Delivers Gene Therapy KENNEDY SPACE…

4 hours ago